Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Protease Inhibitors | 16 | 2025 | 111 | 4.130 |
Why?
|
| HIV-1 | 19 | 2025 | 710 | 3.370 |
Why?
|
| HIV Protease | 13 | 2025 | 127 | 2.900 |
Why?
|
| Drug Resistance, Viral | 19 | 2025 | 167 | 2.540 |
Why?
|
| Antiviral Agents | 17 | 2025 | 332 | 2.380 |
Why?
|
| Viral Nonstructural Proteins | 14 | 2022 | 99 | 2.180 |
Why?
|
| Hepacivirus | 12 | 2022 | 136 | 2.090 |
Why?
|
| Protease Inhibitors | 13 | 2022 | 109 | 1.890 |
Why?
|
| Quinoxalines | 7 | 2022 | 38 | 1.700 |
Why?
|
| Structure-Activity Relationship | 21 | 2026 | 357 | 1.580 |
Why?
|
| Anti-HIV Agents | 5 | 2019 | 139 | 1.530 |
Why?
|
| Molecular Structure | 16 | 2026 | 315 | 1.310 |
Why?
|
| Macrocyclic Compounds | 3 | 2021 | 12 | 1.240 |
Why?
|
| Crystallography, X-Ray | 19 | 2025 | 415 | 1.220 |
Why?
|
| Organoselenium Compounds | 1 | 2026 | 3 | 0.960 |
Why?
|
| Selenium | 1 | 2026 | 27 | 0.930 |
Why?
|
| Indans | 1 | 2025 | 16 | 0.930 |
Why?
|
| Imidazoles | 1 | 2026 | 82 | 0.920 |
Why?
|
| Drug Design | 13 | 2022 | 139 | 0.910 |
Why?
|
| Sulfonamides | 9 | 2022 | 135 | 0.870 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2026 | 155 | 0.840 |
Why?
|
| Models, Molecular | 17 | 2025 | 1161 | 0.790 |
Why?
|
| Darunavir | 6 | 2023 | 34 | 0.720 |
Why?
|
| Prostatic Neoplasms | 1 | 2026 | 502 | 0.680 |
Why?
|
| Furans | 2 | 2020 | 28 | 0.660 |
Why?
|
| Hepatitis C | 3 | 2021 | 145 | 0.650 |
Why?
|
| Antineoplastic Agents | 1 | 2026 | 645 | 0.650 |
Why?
|
| Stereoisomerism | 6 | 2025 | 52 | 0.640 |
Why?
|
| Serine Endopeptidases | 12 | 2022 | 125 | 0.600 |
Why?
|
| Virus Replication | 2 | 2012 | 323 | 0.590 |
Why?
|
| Molecular Docking Simulation | 5 | 2026 | 81 | 0.590 |
Why?
|
| Viral Proteins | 4 | 2025 | 273 | 0.530 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2025 | 207 | 0.510 |
Why?
|
| Catalytic Domain | 11 | 2024 | 200 | 0.510 |
Why?
|
| Positive Transcriptional Elongation Factor B | 3 | 2016 | 9 | 0.500 |
Why?
|
| Nucleoside-Triphosphatase | 10 | 2020 | 43 | 0.460 |
Why?
|
| Molecular Dynamics Simulation | 6 | 2024 | 136 | 0.450 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2025 | 859 | 0.440 |
Why?
|
| HeLa Cells | 7 | 2026 | 541 | 0.440 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 2 | 2012 | 13 | 0.440 |
Why?
|
| Ligands | 5 | 2025 | 414 | 0.430 |
Why?
|
| Enterovirus D, Human | 2 | 2025 | 11 | 0.430 |
Why?
|
| DEAD-box RNA Helicases | 10 | 2020 | 134 | 0.430 |
Why?
|
| Lactams, Macrocyclic | 5 | 2022 | 32 | 0.420 |
Why?
|
| Cysteine Endopeptidases | 2 | 2025 | 96 | 0.410 |
Why?
|
| Cyclopropanes | 5 | 2022 | 57 | 0.410 |
Why?
|
| Protein Binding | 13 | 2025 | 1638 | 0.410 |
Why?
|
| Oxazolidinones | 2 | 2010 | 16 | 0.390 |
Why?
|
| Carrier Proteins | 3 | 2014 | 719 | 0.370 |
Why?
|
| Mutation | 12 | 2025 | 2674 | 0.360 |
Why?
|
| Proline | 3 | 2022 | 46 | 0.350 |
Why?
|
| Leucine | 3 | 2022 | 65 | 0.350 |
Why?
|
| Amides | 4 | 2020 | 61 | 0.340 |
Why?
|
| Aminoisobutyric Acids | 2 | 2022 | 9 | 0.330 |
Why?
|
| Aminopeptidases | 2 | 2022 | 26 | 0.330 |
Why?
|
| Serine Proteases | 2 | 2021 | 13 | 0.330 |
Why?
|
| Flavonoids | 2 | 2010 | 57 | 0.310 |
Why?
|
| Piperidines | 2 | 2010 | 73 | 0.310 |
Why?
|
| Humans | 36 | 2026 | 65831 | 0.310 |
Why?
|
| Drug Resistance, Multiple, Viral | 4 | 2018 | 14 | 0.300 |
Why?
|
| Substrate Specificity | 7 | 2024 | 345 | 0.300 |
Why?
|
| Cell Survival | 3 | 2026 | 588 | 0.300 |
Why?
|
| HEK293 Cells | 3 | 2020 | 617 | 0.280 |
Why?
|
| Halogenation | 2 | 2025 | 6 | 0.280 |
Why?
|
| HIV Infections | 4 | 2023 | 961 | 0.270 |
Why?
|
| Oxazoles | 1 | 2006 | 10 | 0.250 |
Why?
|
| Ubiquinone | 1 | 2026 | 22 | 0.240 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2026 | 44 | 0.240 |
Why?
|
| Peptide Hydrolases | 2 | 2023 | 79 | 0.230 |
Why?
|
| Cell Proliferation | 2 | 2026 | 1044 | 0.230 |
Why?
|
| Dipeptides | 2 | 2020 | 69 | 0.220 |
Why?
|
| Enzyme Inhibitors | 2 | 2021 | 372 | 0.220 |
Why?
|
| Cell Line | 4 | 2019 | 2031 | 0.200 |
Why?
|
| Protein Conformation | 6 | 2025 | 793 | 0.200 |
Why?
|
| Flavivirus | 1 | 2022 | 8 | 0.190 |
Why?
|
| Benzoic Acid | 1 | 2022 | 2 | 0.190 |
Why?
|
| Zika Virus | 1 | 2022 | 38 | 0.180 |
Why?
|
| Small Molecule Libraries | 2 | 2013 | 57 | 0.180 |
Why?
|
| Zika Virus Infection | 1 | 2022 | 39 | 0.180 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2021 | 5 | 0.170 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2021 | 37 | 0.170 |
Why?
|
| Sulfones | 1 | 2020 | 43 | 0.160 |
Why?
|
| Carbamates | 7 | 2020 | 27 | 0.160 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2020 | 50 | 0.160 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2020 | 10 | 0.160 |
Why?
|
| Tryptamines | 1 | 2019 | 13 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 626 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2021 | 118 | 0.150 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 32 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 9 | 3 | 2016 | 8 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 126 | 0.150 |
Why?
|
| Cytidine Deaminase | 2 | 2012 | 86 | 0.150 |
Why?
|
| Hydrogen Bonding | 1 | 2019 | 128 | 0.150 |
Why?
|
| Drug Discovery | 4 | 2021 | 96 | 0.140 |
Why?
|
| Rats | 1 | 2021 | 2005 | 0.130 |
Why?
|
| Peptides, Cyclic | 1 | 2017 | 23 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2014 | 345 | 0.120 |
Why?
|
| Dengue Virus | 1 | 2017 | 101 | 0.120 |
Why?
|
| Exoribonucleases | 1 | 2016 | 30 | 0.120 |
Why?
|
| Binding Sites | 3 | 2018 | 922 | 0.110 |
Why?
|
| Kinetics | 5 | 2018 | 758 | 0.110 |
Why?
|
| Enterovirus Infections | 2 | 2025 | 12 | 0.110 |
Why?
|
| Isoquinolines | 1 | 2014 | 30 | 0.110 |
Why?
|
| Genotype | 1 | 2016 | 676 | 0.110 |
Why?
|
| Viral Structural Proteins | 1 | 2013 | 17 | 0.100 |
Why?
|
| Hyphae | 1 | 2013 | 17 | 0.100 |
Why?
|
| Oligopeptides | 3 | 2015 | 135 | 0.100 |
Why?
|
| Candida albicans | 1 | 2013 | 61 | 0.100 |
Why?
|
| Piperazines | 1 | 2013 | 86 | 0.100 |
Why?
|
| Morphogenesis | 1 | 2013 | 120 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2013 | 218 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 80 | 0.090 |
Why?
|
| Male | 2 | 2026 | 31403 | 0.090 |
Why?
|
| Amino Acid Sequence | 3 | 2021 | 1590 | 0.090 |
Why?
|
| Fluorescence Resonance Energy Transfer | 3 | 2009 | 84 | 0.090 |
Why?
|
| RNA Interference | 2 | 2005 | 647 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2022 | 36 | 0.080 |
Why?
|
| Cyclin T | 1 | 2010 | 1 | 0.080 |
Why?
|
| Genes, Viral | 1 | 2010 | 57 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2010 | 49 | 0.080 |
Why?
|
| Indoles | 2 | 2012 | 112 | 0.080 |
Why?
|
| Animals | 4 | 2026 | 21491 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 1980 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 95 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1635 | 0.070 |
Why?
|
| Cytosine Deaminase | 1 | 2008 | 6 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2005 | 993 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2021 | 52 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 129 | 0.070 |
Why?
|
| Gene Products, tat | 2 | 2004 | 14 | 0.060 |
Why?
|
| Histones | 1 | 2010 | 497 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2026 | 143 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2005 | 4 | 0.060 |
Why?
|
| Static Electricity | 2 | 2016 | 172 | 0.050 |
Why?
|
| RNA Transport | 1 | 2004 | 31 | 0.050 |
Why?
|
| Female | 1 | 2026 | 34419 | 0.050 |
Why?
|
| Kidney | 1 | 2026 | 460 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2016 | 391 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 488 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 196 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2008 | 829 | 0.050 |
Why?
|
| Fluorine | 1 | 2022 | 9 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2013 | 2194 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2022 | 180 | 0.040 |
Why?
|
| Orthomyxoviridae | 1 | 2021 | 29 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2016 | 963 | 0.040 |
Why?
|
| APOBEC-3G Deaminase | 2 | 2012 | 21 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 672 | 0.040 |
Why?
|
| Mice | 3 | 2026 | 11185 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 197 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 369 | 0.040 |
Why?
|
| Crystallography | 2 | 2009 | 26 | 0.030 |
Why?
|
| Peptides | 1 | 2022 | 593 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 238 | 0.030 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 2 | 2010 | 13 | 0.030 |
Why?
|
| Aprotinin | 1 | 2017 | 11 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 518 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2021 | 718 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 50 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2017 | 281 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2016 | 200 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2016 | 144 | 0.030 |
Why?
|
| Microsomes | 1 | 2013 | 10 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2020 | 773 | 0.020 |
Why?
|
| Polystyrenes | 1 | 2013 | 35 | 0.020 |
Why?
|
| Nematoda | 1 | 2013 | 33 | 0.020 |
Why?
|
| Isoindoles | 1 | 2012 | 3 | 0.020 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2012 | 9 | 0.020 |
Why?
|
| Lactams | 1 | 2012 | 21 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2012 | 28 | 0.020 |
Why?
|
| HIV Integrase | 1 | 2012 | 7 | 0.020 |
Why?
|
| Ribonuclease H | 1 | 2012 | 19 | 0.020 |
Why?
|
| Chromatin | 1 | 2016 | 643 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 414 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 3169 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2010 | 52 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2010 | 87 | 0.020 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2010 | 81 | 0.020 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2009 | 6 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 198 | 0.020 |
Why?
|
| Lopinavir | 1 | 2007 | 5 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2007 | 18 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 91 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 279 | 0.010 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2005 | 72 | 0.010 |
Why?
|
| Biopolymers | 1 | 2004 | 72 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 2003 | 8 | 0.010 |
Why?
|
| Peptide Library | 1 | 2003 | 33 | 0.010 |
Why?
|
| Automation | 1 | 2003 | 55 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2003 | 39 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2004 | 283 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2003 | 137 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 1060 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 2003 | 241 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2004 | 419 | 0.010 |
Why?
|
| Nanostructures | 1 | 2004 | 187 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 1332 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2003 | 312 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 427 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 1193 | 0.010 |
Why?
|